Iterum Therapeutics Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules DUBLIN, Ireland and CHICAGO, June 30, 2020 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on...
Neurana Pharmaceuticals Announces First Patient Enrolled in CNS Effects Clinical Study SAN DIEGO, Calif., June 8, 2020 – Neurana Pharmaceuticals, Inc., a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced that...
KLAS Rates TigerConnect Among Top Advanced Clinical Communication Platforms KLAS recognizes TigerConnect for its highly customer-centric, very large customer base across inpatient and non-inpatient care settings, delivering nimble development and “most extensive...
Aptinyx Completes Enrollment in Phase 2 Exploratory Study of NYX-783 in Post-Traumatic Stress Disorder EVANSTON, Ill., June 18, 2020 (GLOBE NEWSWIRE) — Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies...
Iterum Therapeutics Announces Topline Results from its Phase 3 Clinical Trial of Oral Sulopenem for the Treatment of Uncomplicated Urinary Tract Infections Sulopenem demonstrates superiority in treatment of patients with quinolone resistant pathogens Company to...
Principia Announces First Patient Enrolled in Sanofi’s Phase 3 Trial of SAR442168 in Relapsing Multiple Sclerosis Dosing of Patient Will Trigger $50 Million Milestone Payment SOUTH SAN FRANCISCO, Calif., June 23, 2020 (GLOBE NEWSWIRE) — Principia Biopharma Inc....
Recent Comments